Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.
Zist Daru, ZIFERON
Viral triggers of multiple sclerosis.
Pages
« first
‹ previous
…
13
14
15
16
17
18
19
20
21
…
next ›
last »